{"id": "article-125954_0", "title": "Drug Distribution -- Definition/Introduction", "content": "Pharmacokinetics is the study of a drug moiety or a compound as it moves through the body after its administration. It involves the processes of drug absorption, bioavailability, clearance, and distribution. [1] Although these processes are theoretically separate, from a practical standpoint in-vivo, they are all inter-connected. After the drug is absorbed from the site of administration, it is distributed to extracellular fluids. [2] High reserves of plasma protein-bound drugs can cause prolonged effects by creating a sustained release mechanism. [3]", "contents": "Drug Distribution -- Definition/Introduction. Pharmacokinetics is the study of a drug moiety or a compound as it moves through the body after its administration. It involves the processes of drug absorption, bioavailability, clearance, and distribution. [1] Although these processes are theoretically separate, from a practical standpoint in-vivo, they are all inter-connected. After the drug is absorbed from the site of administration, it is distributed to extracellular fluids. [2] High reserves of plasma protein-bound drugs can cause prolonged effects by creating a sustained release mechanism. [3]"}
{"id": "article-125954_1", "title": "Drug Distribution -- Definition/Introduction", "content": "Drug distribution is the disbursement of an unmetabolized drug as it moves through the body\u2019s blood and tissues. The efficacy or toxicity of a drug depends on the distribution in specific tissues and in part explains the lack of correlation between plasma levels and the effects that are seen. Based on the molecular structure, drugs have variable distribution in different types of tissues such as fat, muscle, and brain. Unlike other tissues, the brain and testes are unique, as they contain membrane barriers making a drug significantly less susceptible to distribution. [4] Based on lipid and non-lipid solubility, drugs can be classified as lipophilic or hydrophilic described below.", "contents": "Drug Distribution -- Definition/Introduction. Drug distribution is the disbursement of an unmetabolized drug as it moves through the body\u2019s blood and tissues. The efficacy or toxicity of a drug depends on the distribution in specific tissues and in part explains the lack of correlation between plasma levels and the effects that are seen. Based on the molecular structure, drugs have variable distribution in different types of tissues such as fat, muscle, and brain. Unlike other tissues, the brain and testes are unique, as they contain membrane barriers making a drug significantly less susceptible to distribution. [4] Based on lipid and non-lipid solubility, drugs can be classified as lipophilic or hydrophilic described below."}
{"id": "article-125954_2", "title": "Drug Distribution -- Definition/Introduction -- Lipophiliic (Fat Soluble)", "content": "Nonpolar compounds Easily diffuse across lipid bilayers of cell membranes Rx can be administered topically Free diffusion across the blood-brain barrier Biotransformed in the liver Excreted through the bile duct", "contents": "Drug Distribution -- Definition/Introduction -- Lipophiliic (Fat Soluble). Nonpolar compounds Easily diffuse across lipid bilayers of cell membranes Rx can be administered topically Free diffusion across the blood-brain barrier Biotransformed in the liver Excreted through the bile duct"}
{"id": "article-125954_3", "title": "Drug Distribution -- Definition/Introduction -- Hydrophilic (Water Soluble)", "content": "Polar compounds Cross lipid bilayers via facilitated transport (passive chemical diffusion across a cell membrane by ion channels or carriers) Eliminated by kidneys", "contents": "Drug Distribution -- Definition/Introduction -- Hydrophilic (Water Soluble). Polar compounds Cross lipid bilayers via facilitated transport (passive chemical diffusion across a cell membrane by ion channels or carriers) Eliminated by kidneys"}
{"id": "article-125954_4", "title": "Drug Distribution -- Issues of Concern", "content": "Drug distribution is impacted by several factors related to the drug and the body. The drug-related factors include blood and tissue binding proteins, pH, and perfusion. The body-related factors include body water composition, fat composition, diseases (e.g., volume depletion, burns, third spacing).", "contents": "Drug Distribution -- Issues of Concern. Drug distribution is impacted by several factors related to the drug and the body. The drug-related factors include blood and tissue binding proteins, pH, and perfusion. The body-related factors include body water composition, fat composition, diseases (e.g., volume depletion, burns, third spacing)."}
{"id": "article-125954_5", "title": "Drug Distribution -- Clinical Significance", "content": "As\u00a0people age, the overall body water reduces. However, intracellular water remains relatively stable from the first month of life to adulthood. Higher doses of drugs per kilogram weight are required in younger children as they have a higher percentage of water. [5] Lipophilic drugs are more likely to distribute to areas of high lipid density. [6] Body fat varies with age, gender and genetics. Many drugs are bound to plasma proteins, and the most important drug-binding proteins include albumin and globulins. The concentration of these proteins varies with age, nutritional status, and disease.", "contents": "Drug Distribution -- Clinical Significance. As\u00a0people age, the overall body water reduces. However, intracellular water remains relatively stable from the first month of life to adulthood. Higher doses of drugs per kilogram weight are required in younger children as they have a higher percentage of water. [5] Lipophilic drugs are more likely to distribute to areas of high lipid density. [6] Body fat varies with age, gender and genetics. Many drugs are bound to plasma proteins, and the most important drug-binding proteins include albumin and globulins. The concentration of these proteins varies with age, nutritional status, and disease."}
{"id": "article-125954_6", "title": "Drug Distribution -- Clinical Significance", "content": "Understanding drug distribution and pharmacokinetics (PK) is important for all clinicians prescribing medication, along with understanding the\u00a0fundamentals of protein binding. [7] Only\u00a0free and unbound drugs will pass from vascular spaces to tissues where a drug-receptor interaction will occur as well\u00a0as the effect of the drug.\u00a0Protein binding is not only affected by the concentration of protein but also the pH, metabolic abnormalities (hyperglycemia, uremia), and the presence of other chemicals that will compete for protein binding.", "contents": "Drug Distribution -- Clinical Significance. Understanding drug distribution and pharmacokinetics (PK) is important for all clinicians prescribing medication, along with understanding the\u00a0fundamentals of protein binding. [7] Only\u00a0free and unbound drugs will pass from vascular spaces to tissues where a drug-receptor interaction will occur as well\u00a0as the effect of the drug.\u00a0Protein binding is not only affected by the concentration of protein but also the pH, metabolic abnormalities (hyperglycemia, uremia), and the presence of other chemicals that will compete for protein binding."}
{"id": "article-125954_7", "title": "Drug Distribution -- Clinical Significance", "content": "Competition for plasma binding can influence drug effects. For example, Aspirin and Warfarin are known to compete for the same plasma protein binding site. Administering both drugs at the same time will increase the unbound drug, thereby potentiating their effects and potentially lead to bleeding risk. [8] For a drug to be effectively eliminated by the kidney, the drug must be metabolized from a lipophilic molecule into a polar molecule. The liver produces a polar metabolite of the drug, using two unique sets of reactions known as phase I metabolism and phase II metabolism. [9]", "contents": "Drug Distribution -- Clinical Significance. Competition for plasma binding can influence drug effects. For example, Aspirin and Warfarin are known to compete for the same plasma protein binding site. Administering both drugs at the same time will increase the unbound drug, thereby potentiating their effects and potentially lead to bleeding risk. [8] For a drug to be effectively eliminated by the kidney, the drug must be metabolized from a lipophilic molecule into a polar molecule. The liver produces a polar metabolite of the drug, using two unique sets of reactions known as phase I metabolism and phase II metabolism. [9]"}
{"id": "article-125954_8", "title": "Drug Distribution -- Clinical Significance", "content": "Phase I metabolism involves what is known as the cytochrome P-450 system (CYP enzyme). CYP alters a drug in such a way so that it will be more amenable to combining with polar molecules. These reactions involve basic chemistry principles such as oxidation, reduction, or hydrolysis. Phase II metabolism is the process of adding a polar moiety to the drug, such as sulfate, acetate, or glucuronate. The addition of a polar moiety to a drug makes the drug water-soluble and available for excretion\u00a0by the kidney.", "contents": "Drug Distribution -- Clinical Significance. Phase I metabolism involves what is known as the cytochrome P-450 system (CYP enzyme). CYP alters a drug in such a way so that it will be more amenable to combining with polar molecules. These reactions involve basic chemistry principles such as oxidation, reduction, or hydrolysis. Phase II metabolism is the process of adding a polar moiety to the drug, such as sulfate, acetate, or glucuronate. The addition of a polar moiety to a drug makes the drug water-soluble and available for excretion\u00a0by the kidney."}
{"id": "article-125954_9", "title": "Drug Distribution -- Clinical Significance -- Phases of Biotransformation", "content": "Phase I reaction : The drug is first transformed into a polar metabolite via oxidation by the cytochrome P-450 system\u00a0\u2192\u00a0allows\u00a0phase II to occur. Phase II reactions : Involves the coupling of the metabolite with\u00a0glucuronic acid, acetyl groups, sulfates, amino acids, or glutathione.", "contents": "Drug Distribution -- Clinical Significance -- Phases of Biotransformation. Phase I reaction : The drug is first transformed into a polar metabolite via oxidation by the cytochrome P-450 system\u00a0\u2192\u00a0allows\u00a0phase II to occur. Phase II reactions : Involves the coupling of the metabolite with\u00a0glucuronic acid, acetyl groups, sulfates, amino acids, or glutathione."}
{"id": "article-125954_10", "title": "Drug Distribution -- Clinical Significance -- Types of Drug Kinetics", "content": "Zero-order kinetics : The rate of metabolism/elimination remains constant and is\u00a0independent of the concentration of a drug. First-order kinetics : The rate of metabolism/elimination is directly\u00a0proportional to the plasma concentration of the drug. Half-life (T1/2): The\u00a0time required for a drug's plasma concentration to reach half of its initial value. After 4 half-lives > 90%\u00a0of the drug is eliminated. Drug clearance: The\u00a0measure of the rate of drug elimination \u2192 the plasma volume that can be completely cleared of the drug in a given period of time.", "contents": "Drug Distribution -- Clinical Significance -- Types of Drug Kinetics. Zero-order kinetics : The rate of metabolism/elimination remains constant and is\u00a0independent of the concentration of a drug. First-order kinetics : The rate of metabolism/elimination is directly\u00a0proportional to the plasma concentration of the drug. Half-life (T1/2): The\u00a0time required for a drug's plasma concentration to reach half of its initial value. After 4 half-lives > 90%\u00a0of the drug is eliminated. Drug clearance: The\u00a0measure of the rate of drug elimination \u2192 the plasma volume that can be completely cleared of the drug in a given period of time."}
{"id": "article-125954_11", "title": "Drug Distribution -- Clinical Significance", "content": "Additionally, uremia not only affects protein binding, but kidneys also play a significant role in drug absorption, distribution, metabolism, and excretion (ADME). Renal dose adjustment is essential in moderate to severe renal failure. Important strategies for managing and drug dosing must be adjusted accordingly, and the risks must be weighed against the benefits. [10]", "contents": "Drug Distribution -- Clinical Significance. Additionally, uremia not only affects protein binding, but kidneys also play a significant role in drug absorption, distribution, metabolism, and excretion (ADME). Renal dose adjustment is essential in moderate to severe renal failure. Important strategies for managing and drug dosing must be adjusted accordingly, and the risks must be weighed against the benefits. [10]"}
{"id": "article-125954_12", "title": "Drug Distribution -- Clinical Significance", "content": "Several factors impact drug distribution. These factors include the concentration of drug transporters in blood, pH, perfusion, body water composition, body fat composition, and most certainly disease conditions (e.g., volume depletion, burns, third spacing). The majority of protein binding is relevant only when the drug is more than 90 percent protein bound. In the hypoalbuminemia state, which occurs in malnutrition and inflammation, there is a higher concentration of the unbound drugs. Body composition and metabolic factors also affect drug distribution. For example, during the last trimester of pregnancy, plasma volume expands, so there is an overall diluting effect on plasma proteins. There is also a change in adipose tissue. Additionally, pregnant women are frequently excluded in clinical trials related to drugs. [11] In a critically ill patient, drug distribution also changes due to deranged physiology, protein binding changes, fluid shifts, pH changes, and vascular organ perfusion. [12] Thus it could be useful to monitor drug levels in these conditions if possible.", "contents": "Drug Distribution -- Clinical Significance. Several factors impact drug distribution. These factors include the concentration of drug transporters in blood, pH, perfusion, body water composition, body fat composition, and most certainly disease conditions (e.g., volume depletion, burns, third spacing). The majority of protein binding is relevant only when the drug is more than 90 percent protein bound. In the hypoalbuminemia state, which occurs in malnutrition and inflammation, there is a higher concentration of the unbound drugs. Body composition and metabolic factors also affect drug distribution. For example, during the last trimester of pregnancy, plasma volume expands, so there is an overall diluting effect on plasma proteins. There is also a change in adipose tissue. Additionally, pregnant women are frequently excluded in clinical trials related to drugs. [11] In a critically ill patient, drug distribution also changes due to deranged physiology, protein binding changes, fluid shifts, pH changes, and vascular organ perfusion. [12] Thus it could be useful to monitor drug levels in these conditions if possible."}
{"id": "article-125954_13", "title": "Drug Distribution -- Clinical Significance", "content": "The cytochrome P-450 system is a family of heme-containing enzymes found in the liver and intestinal tract. There are multiple forms of CYP enzymes. Some drugs can either induce or inhibit specific isoforms of the enzyme, affecting the ADME of a drug. A clinician must be aware of potential drug-drug interactions with CYP enzyme inducers and inhibitors and\u00a0naturally occurring compounds that can alter the actions of CYP enzyme. Naturally occurring compounds include grapefruit juice, nicotine-containing products, and St. John\u2019s wort. [13] [14] Below is a list of the major drugs that inhibit and induce the cytochrome P-450 system, as well as dugs that are a major substrate of the enzyme:", "contents": "Drug Distribution -- Clinical Significance. The cytochrome P-450 system is a family of heme-containing enzymes found in the liver and intestinal tract. There are multiple forms of CYP enzymes. Some drugs can either induce or inhibit specific isoforms of the enzyme, affecting the ADME of a drug. A clinician must be aware of potential drug-drug interactions with CYP enzyme inducers and inhibitors and\u00a0naturally occurring compounds that can alter the actions of CYP enzyme. Naturally occurring compounds include grapefruit juice, nicotine-containing products, and St. John\u2019s wort. [13] [14] Below is a list of the major drugs that inhibit and induce the cytochrome P-450 system, as well as dugs that are a major substrate of the enzyme:"}
{"id": "article-125954_14", "title": "Drug Distribution -- Clinical Significance -- CYP1A2", "content": "Inhibitors:\u00a0amiodarone, cimetidine, ciprofloxacin, fluvoxamine Inducers:\u00a0carbamazepine, phenobarbital, rifampin, tobacco Substrates:\u00a0caffeine, clozapine, theophylline", "contents": "Drug Distribution -- Clinical Significance -- CYP1A2. Inhibitors:\u00a0amiodarone, cimetidine, ciprofloxacin, fluvoxamine Inducers:\u00a0carbamazepine, phenobarbital, rifampin, tobacco Substrates:\u00a0caffeine, clozapine, theophylline"}
{"id": "article-125954_15", "title": "Drug Distribution -- Clinical Significance -- CYP2C9", "content": "Inhibitors:\u00a0amiodarone, fluconazole, fluoxetine, metronidazole, ritonavir, trimethoprim/sulfamethoxazole Inducers: carbamazepine, phenobarbital, phenytoin, rifampin Substrates:\u00a0carvedilol, celecoxib, glipizide, ibuprofen, irbesartan, losartan", "contents": "Drug Distribution -- Clinical Significance -- CYP2C9. Inhibitors:\u00a0amiodarone, fluconazole, fluoxetine, metronidazole, ritonavir, trimethoprim/sulfamethoxazole Inducers: carbamazepine, phenobarbital, phenytoin, rifampin Substrates:\u00a0carvedilol, celecoxib, glipizide, ibuprofen, irbesartan, losartan"}
{"id": "article-125954_16", "title": "Drug Distribution -- Clinical Significance -- CYP2C19", "content": "Inhibitors:\u00a0fluvoxamine, isoniazid, ritonavir Inducers: carbamazepine, phenytoin, rifampin Substrates:\u00a0omeprazole, phenobarbital, phenytoin", "contents": "Drug Distribution -- Clinical Significance -- CYP2C19. Inhibitors:\u00a0fluvoxamine, isoniazid, ritonavir Inducers: carbamazepine, phenytoin, rifampin Substrates:\u00a0omeprazole, phenobarbital, phenytoin"}
{"id": "article-125954_17", "title": "Drug Distribution -- Clinical Significance -- CYP2D6", "content": "Inhibitors:\u00a0amiodarone, cimetidine, diphenhydramine, fluoxetine, paroxetine, quinidine, ritonavir, terbinafine Inducers: none Substrates: amitriptyline, carvedilol, codeine, donepezil, haloperidol, metoprolol, paroxetine, risperidone, tramadol", "contents": "Drug Distribution -- Clinical Significance -- CYP2D6. Inhibitors:\u00a0amiodarone, cimetidine, diphenhydramine, fluoxetine, paroxetine, quinidine, ritonavir, terbinafine Inducers: none Substrates: amitriptyline, carvedilol, codeine, donepezil, haloperidol, metoprolol, paroxetine, risperidone, tramadol"}
{"id": "article-125954_18", "title": "Drug Distribution -- Clinical Significance -- CYP2E1", "content": "Inhibitors: none Inducers: ethanol, isoniazid, tobacco Substrates: acetaminophen, theophylline, verapamil", "contents": "Drug Distribution -- Clinical Significance -- CYP2E1. Inhibitors: none Inducers: ethanol, isoniazid, tobacco Substrates: acetaminophen, theophylline, verapamil"}
{"id": "article-125954_19", "title": "Drug Distribution -- Clinical Significance -- CYP3A4 and CYP3A5", "content": "Inhibitors:\u00a0clarithromycin, diltiazem, erythromycin, grapefruit juice, itraconazole, ketoconazole, nefazodone * , ritonavir, telithromycin, verapamil Inducers: carbamazepine,\u00a0Hypericum perforatum, phenobarbital, phenytoin, rifampin Substrates:\u00a0alprazolam, amlodipine, atorvastatin, cyclosporine, diazepam, estradiol, simvastatin, sildenafil, verapamil, zolpidem Below is an additional list of common drug-drug interactions involving the cytochrome P-450 system that clinicians should be aware of:", "contents": "Drug Distribution -- Clinical Significance -- CYP3A4 and CYP3A5. Inhibitors:\u00a0clarithromycin, diltiazem, erythromycin, grapefruit juice, itraconazole, ketoconazole, nefazodone * , ritonavir, telithromycin, verapamil Inducers: carbamazepine,\u00a0Hypericum perforatum, phenobarbital, phenytoin, rifampin Substrates:\u00a0alprazolam, amlodipine, atorvastatin, cyclosporine, diazepam, estradiol, simvastatin, sildenafil, verapamil, zolpidem Below is an additional list of common drug-drug interactions involving the cytochrome P-450 system that clinicians should be aware of:"}
{"id": "article-125954_20", "title": "Drug Distribution -- Clinical Significance -- Drug: amiodarone", "content": "CYP enzyme:\u00a0CYP2C9 and CYP3A4 inhibitor Drug-Drug Interaction: warfarin Metabolizing Enzyme:\u00a0CYP2C9 Side Effects: Increased risk of bleeding caused by increased warfarin level. Drug: carbamazepine , phenobarbital , phenytoin CYP enzyme:\u00a0CYP3A4 inducer Drug-Drug Interaction: Ethinyl estradiol-containing contraceptives Metabolizing Enzyme:\u00a0CYP3A4 Side Effects: Unplanned pregnancy caused by reduced estradiol level. Drug: clarithromycin , erythromycin , telithromycin CYP enzyme: CYP3A4 inhibitor Drug-Drug Interaction: simvastatin, verapamil Metabolizing Enzyme:\u00a0CYP3A4 Side Effects: Myopathy or rhabdomyolysis caused by increased simvastatin level. Hypotension and QT interval prolongation caused by increased verapamil level. Drug: diltiazem , verapamil CYP enzyme:\u00a0CYP3A4 inhibitor Drug-Drug Interaction: prednisone Metabolizing Enzyme: CYP3A4 Side Effects: Immunosuppression caused by increased prednisolone serum levels. Drug: fluoxetine , paroxetine CYP enzyme:\u00a0CYP2D6 inhibitor", "contents": "Drug Distribution -- Clinical Significance -- Drug: amiodarone. CYP enzyme:\u00a0CYP2C9 and CYP3A4 inhibitor Drug-Drug Interaction: warfarin Metabolizing Enzyme:\u00a0CYP2C9 Side Effects: Increased risk of bleeding caused by increased warfarin level. Drug: carbamazepine , phenobarbital , phenytoin CYP enzyme:\u00a0CYP3A4 inducer Drug-Drug Interaction: Ethinyl estradiol-containing contraceptives Metabolizing Enzyme:\u00a0CYP3A4 Side Effects: Unplanned pregnancy caused by reduced estradiol level. Drug: clarithromycin , erythromycin , telithromycin CYP enzyme: CYP3A4 inhibitor Drug-Drug Interaction: simvastatin, verapamil Metabolizing Enzyme:\u00a0CYP3A4 Side Effects: Myopathy or rhabdomyolysis caused by increased simvastatin level. Hypotension and QT interval prolongation caused by increased verapamil level. Drug: diltiazem , verapamil CYP enzyme:\u00a0CYP3A4 inhibitor Drug-Drug Interaction: prednisone Metabolizing Enzyme: CYP3A4 Side Effects: Immunosuppression caused by increased prednisolone serum levels. Drug: fluoxetine , paroxetine CYP enzyme:\u00a0CYP2D6 inhibitor"}
{"id": "article-125954_21", "title": "Drug Distribution -- Clinical Significance -- Drug: amiodarone", "content": "Drug-Drug Interaction: risperidone, tramadol Metabolizing Enzyme:\u00a0CYP2D6 Side Effects: Increased risk of extrapyramidal adverse effects caused by increased risperidone level.", "contents": "Drug Distribution -- Clinical Significance -- Drug: amiodarone. Drug-Drug Interaction: risperidone, tramadol Metabolizing Enzyme:\u00a0CYP2D6 Side Effects: Increased risk of extrapyramidal adverse effects caused by increased risperidone level."}
{"id": "article-125954_22", "title": "Drug Distribution -- Clinical Significance -- Drug: Grapefruit juice", "content": "CYP enzyme:\u00a0CYP3A4 inhibitor Drug-Drug Interaction: buspirone Metabolizing Enzyme:\u00a0CYP3A4 Side Effects:\u00a0Dizziness and serotonin syndrome caused by increased buspirone level.", "contents": "Drug Distribution -- Clinical Significance -- Drug: Grapefruit juice. CYP enzyme:\u00a0CYP3A4 inhibitor Drug-Drug Interaction: buspirone Metabolizing Enzyme:\u00a0CYP3A4 Side Effects:\u00a0Dizziness and serotonin syndrome caused by increased buspirone level."}
{"id": "article-125954_23", "title": "Drug Distribution -- Clinical Significance -- Drug: metronidazole", "content": "CYP enzyme:\u00a0CYP2C9 inhibitor Drug-Drug Interaction: warfarin Metabolizing Enzyme:\u00a0CYP2C9 Side Effects: Increased risk of bleeding caused by increased warfarin level.", "contents": "Drug Distribution -- Clinical Significance -- Drug: metronidazole. CYP enzyme:\u00a0CYP2C9 inhibitor Drug-Drug Interaction: warfarin Metabolizing Enzyme:\u00a0CYP2C9 Side Effects: Increased risk of bleeding caused by increased warfarin level."}
{"id": "article-125954_24", "title": "Drug Distribution -- Clinical Significance -- Drug: terbinafine", "content": "CYP enzyme:\u00a0CYP2D6 inhibitor Drug-Drug Interaction: amitriptyline Metabolizing Enzyme:\u00a0CYP2D6 Side Effects:\u00a0Dry mouth, dizziness, and cardiac toxicity caused by a prolonged increase in amitriptyline and nortriptyline. CYP = cytochrome P-450", "contents": "Drug Distribution -- Clinical Significance -- Drug: terbinafine. CYP enzyme:\u00a0CYP2D6 inhibitor Drug-Drug Interaction: amitriptyline Metabolizing Enzyme:\u00a0CYP2D6 Side Effects:\u00a0Dry mouth, dizziness, and cardiac toxicity caused by a prolonged increase in amitriptyline and nortriptyline. CYP = cytochrome P-450"}
{"id": "article-125954_25", "title": "Drug Distribution -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "The interprofessional team and healthcare professionals, including laboratory technologists, pharmacists, nurses, and clinicians, need to all work together to ensure the safety and efficacy of administered drugs. After the clinician chooses the choice and dosage of a particular drug, the pharmacist should verify dosing, report any drug interactions, and take notice of special clinical situations that will influence drug levels and hence efficacy as well as adverse events (e.g., albumin levels, changes in weight, malnutrition, renal and hepatic function).\u00a0In one study in chronic kidney disease patients, pharmacists identified 5302 drug-related problems and made 3160 recommendations with acceptance rates up to 95%. [15]", "contents": "Drug Distribution -- Nursing, Allied Health, and Interprofessional Team Interventions. The interprofessional team and healthcare professionals, including laboratory technologists, pharmacists, nurses, and clinicians, need to all work together to ensure the safety and efficacy of administered drugs. After the clinician chooses the choice and dosage of a particular drug, the pharmacist should verify dosing, report any drug interactions, and take notice of special clinical situations that will influence drug levels and hence efficacy as well as adverse events (e.g., albumin levels, changes in weight, malnutrition, renal and hepatic function).\u00a0In one study in chronic kidney disease patients, pharmacists identified 5302 drug-related problems and made 3160 recommendations with acceptance rates up to 95%. [15]"}
{"id": "article-125954_26", "title": "Drug Distribution -- Nursing, Allied Health, and Interprofessional Team Interventions", "content": "When possible and indicated plasma levels should be followed. Nurses play a critical role in drug administration and alerting the team regarding\u00a0errors related to medication reconciliation. [16] This team collaboration is an essential part of\u00a0patient safety in the inpatient and outpatient setting.", "contents": "Drug Distribution -- Nursing, Allied Health, and Interprofessional Team Interventions. When possible and indicated plasma levels should be followed. Nurses play a critical role in drug administration and alerting the team regarding\u00a0errors related to medication reconciliation. [16] This team collaboration is an essential part of\u00a0patient safety in the inpatient and outpatient setting."}
{"id": "article-125954_27", "title": "Drug Distribution -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Drug Distribution -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}